Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Auteur de référence en rhumatologie
26 articles scientifiques publiés — un praticien à la pointe de la recherche
Disponibilité géographique
2 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
136 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
35
35 articles ont été cités au moins 35fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
4 212
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
194
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
67
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Immune dysregulation through longitudinal lymphocyte trajectories and their clinical determinants in hospitalized COVID-19 patients
2026ArticleIntensive Care Medicine Experimental
Patient-reported outcomes among people living with HIV switching to dual therapy with dolutegravir/lamivudine: results from the PROBI study
2025ArticleTherapeutic Advances in Infectious Disease
Sex Differences in Patient‐Reported Outcomes Among People Living With HIV Switching to an Oral Dual Therapy: Results From the PROBI Study
2025ArticleAIDS Research and Treatment
Low CD4 cell count is associated with post-hepatitis C virus cure mortality in people living with HIV (ANRS CO13 HEPAVIH cohort)
2025ArticleClinical Infectious Diseases
Gender differences in patient-reported outcomes among people living with HIV switching to an oral dual therapy: PROBI study
2024Congrès31st Annual Conference of the International Society for Quality of Life Research
Acceptability determinants of a proposal to reduce antiretroviral treatment to an oral two-drug regimen among patients living with HIV and physicians in France
2024ArticlePLoS ONE
At-admission prediction of mortality and pulmonary embolism in an international cohort of hospitalised patients with COVID-19 using statistical and machine learning methods
2024ArticleScientific Reports
Humoral response after mRNA COVID-19 primary vaccination and single booster dose in people living with HIV compared to controls: a French nationwide multicenter cohort study - ANRS0001s COV-POPART
2024ArticleInternational Journal of Infectious Diseases
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
HOPITAL FOCH
40 R WORTH BP 36, 92151 SURESNES CEDEX
CDS FOCH PARIS LA DEFENSE
12 PL DES REFLETS, 92400 COURBEVOIE
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Travel medicine and infectious disease · 2022
Journal of the International AIDS Society · 2020
AbstractIntroductionDespite the advent of HIV cure‐related clinical trials (HCRCT) for people living with HIV (PLWH), the risks and uncertainty involved raise ethical issues. Although research has provided insights into the levers and barriers to PLWH and physicians' participation in these trials, no information exists about stakeholders' preferences for HCRCT attributes, about the different ways PLWH and physicians value future HCRCT, or about how personal characteristics affect these preferences. The results from the present study will inform researchers' decisions about the most suitable HCRCT strategies to implement, and help them ensure ethical recruitment and well‐designed informed consent.MethodsBetween October 2016 and March 2017, a discrete choice experiment was conducted among 195 virally controlled PLWH and 160 physicians from 24 French HIV centres. Profiles within each group, based on individual characteristics, were obtained using hierarchical clustering. Trade‐offs between five HCRCT attributes (trial duration, consultation frequency, moderate (digestive disorders, flu‐type syndrome, fatigue) and severe (allergy, infections, risk of cancer) side effects (SE), outcomes) and utilities associated with four HCRCT candidates (latency reactivation, immunotherapy, gene therapy and a combination of latency reactivation and immunotherapy), were estimated using a mixed logit model.ResultsApart from severe SE – the most decisive attribute in both groups – PLWH and physicians made different trade‐offs between HCRCT attributes, the latter being more concerned about outcomes, the former about the burden of participation (consultation frequency and moderate SE). These different trades‐offs resulted in differences in preferences regarding the four candidate HCRCT. PLWH significantly preferred immunotherapy, whereas physicians preferred immunotherapy and combined therapy. Despite the heterogeneity of characteristics within the PLWH and physician profiles, results show some homogeneity in trade‐offs and utilities regarding HCRCT.ConclusionsSevere SE, not outcomes, was the most decisive attribute determining future HCRCT participation. Particular attention should be paid to providing clear information, in particular on severe SE, to potential participants. Immunotherapy would appear to be the best HCRCT candidate for both PLWH and physicians. However, if the risk of cancer could be avoided, gene therapy would become the preferred strategy for the latter and the second choice for the former.
Journal of viral hepatitis · 2019
SummaryWorldwide, hepatocellular carcinoma (HCC) occurs mainly in Asian patients with hepatitis B virus (HBV) infection. This study aimed to decipher the environmental and virological factors associated with HCC occurrence and validate risk scoring systems in a French multicentre prospective cohort of HBV cirrhotic patients. Patients with biopsy‐proven Child‐Pugh A viral cirrhosis included in the ANRS CO12 CirVir cohort who were HBsAg(+) without hepatitis C coinfection were selected for: (a) interview through a standardized questionnaire reporting coffee consumption and HCC familial history; (b) HBsAg quantification using baseline and sequential 2‐year frozen sera; (c) baseline HBV genotype determination; and (d) assessment of risk factors and applicability of HCC risk scores (Kaplan‐Meier analysis, Cox models). Among 317 patients studied (261 men, median age 53 years, past or ongoing antiviral treatment 93.3% and baseline detectable HBV DNA in 88 patients), the baseline and 2‐year median HBsAg levels were 810 and 463 IU/mL, respectively. After a median follow‐up of 65.2 months, 27 HCC cases were diagnosed (annual incidence: 1.6%). Three factors were independently associated with HCC occurrence: age > 50 years, platelets ≤ 150 × 103/mm3 and body mass index ≥ 30 kg/m2. Two out of five risk scores were validated, and the most accurate was PAGE‐B at 1 year. Moreover, HCC in patients without maintained virological suppression seems more aggressive and less accessible to curative treatment. In conclusion, in French patients with HBV cirrhosis mostly virally suppressed, independent HCC risk factors were host‐related (age, obesity) or linked to the severity of cirrhosis (thrombopenia), and the European PAGE‐B score was the most accurate risk score.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025 · Editorial
Barré T, Ramier C, Wittkop L, Sogni P, et al.
International journal of radiation oncology, biology, physics · 2024 · Journal Article
Evin C, Quéro L, Le Malicot K, Blanchet-Deverly S, et al.
European journal of public health · 2024 · Journal Article
Vallée A, Majerholc C, Zucman D, Livrozet JM, et al.
PloS one · 2024 · Journal Article
Petit AS, Allavena C, Zucman D, Hocqueloux L, et al.
Diagnostic microbiology and infectious disease · 2024 · Journal Article
Farfour E, Kitous C, Zucman D, Touche P, et al.
Journal of viral hepatitis · 2023 · Letter
Barré T, Zucman D, Marcellin F, Ramier C, et al.
BMC health services research · 2022 · Journal Article
Vallée A, Sveltlane D, Trichereau J, Neveu S, et al.
The International journal on drug policy · 2022 · Journal Article
Marcellin F, Zucman D, Ramier C, Lotto M, et al.
HIV medicine · 2021 · Journal Article
Chalouni M, Pol S, Sogni P, Fontaine H, et al.
HIV medicine · 2021 · Journal Article
Chalouni M, Wittkop L, Bani-Sadr F, Lacombe K, et al.
Journal of clinical medicine · 2021 · Journal Article
Vallée A, Vasse M, Mazaux L, Bonan B, et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020 · Letter
Marcellin F, Miailhes P, Santos M, Mercié P, et al.
PloS one · 2020 · Journal Article
Giraud JS, Doisne M, Chan Hew Wai A, Majerholc C, et al.
The Journal of infectious diseases · 2020 · Journal Article
Costagliola D, Potard V, Lang S, de Castro N, et al.
Journal of viral hepatitis · 2019 · Journal Article
Brichler S, Nahon P, Zoulim F, Layese R, et al.
PloS one · 2018 · Journal Article
Billa O, Chalouni M, Salmon D, Poizot-Martin I, et al.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2024 · Journal Article
Loubet P, Lelievre JD, François A, Botelho-Nevers E, et al.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2023 · Journal Article
Ghosn J, Bachelet D, Livrozet M, Cervantes-Gonzalez M, et al.
Therapeutic advances in infectious disease · 2025 · Journal Article
Duracinsky M, Alain T, Zucman D, Rousset Torrente O, et al.
AIDS research and treatment · 2025 · Journal Article
Alain T, Marcellin F, Bessonneau P, Hocqueloux L, et al.
Travel medicine and infectious disease · 2022 · Case Reports
Vallée A, Farfour E, Zucman D
PloS one · 2024 · Journal Article
Roucoux G, Thonon F, Zucman D, Rey D, et al.
Journal of the International AIDS Society · 2020 · Journal Article
Protiere C, Arnold M, Fiorentino M, Fressard L, et al.
HIV medicine · 2026 · Journal Article
Mussini C, Henegar C, Assoumou L, de Wit S, et al.
Expert review of anti-infective therapy · 2021 · Journal Article
Barré T, Rojas Rojas T, Lacombe K, Protopopescu C, et al.
HIV medicine · 2026 · Journal Article
Mussini C, Henegar C, Assoumou L, de Wit S, et al.
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
PloS one · 2019 · Journal Article
Shili-Masmoudi S, Sogni P, de Ledinghen V, Esterle L, et al.